RemeGen Raises $515 Million in Hong Kong IPO, Company Valued at $4.3 Billion
publication date: Nov 12, 2020
RemeGen, a Yantai biotech approaching commercial stage, completed a $515 million IPO on the Hong Kong exchange in the largest biotech IPO of the year. Founded in 2008, RemeGen is developing a portfolio of ten novel mAbs, fusion proteins, antibody-drug conjugates (ADCs) and bifunctional antibodies. Two of its candidates are under NDA review in China: telitacicept for autoimmune diseases (systemic lupus erythematosus) and disitamab vedotin for HER2 cancers. The company's shares have traded 34% higher since the IPO, giving RemeGen a market capitalization of $4.3 billion. More details....
Stock Symbol: (HK: 9995)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.